Clinical trials: Choroid Diseases
Glaucoma
Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.
Evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angle glaucoma.
- Trial name
- STAR-V (NCT05024695)
- Testing
- MINIject™ Implant
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 975 people
- Sponsor
- iSTAR Medical
Birdshot Chorioretinopathy, Posterior Uveitis
Birdshot Chorioretinopathy : Prospective Follow-up and Immunogenetic Studies(CO-BIRD)
The purpose of this study is twofold: 1. To analyze the clinical features of a cohort of patients with birdshot chorioretinopathy (BCR), an inflammatory bilateral ocular disease, affecting the choroid and the retina.
- Trial name
- CO-BIRD (NCT05153057)
- Testing
- Observational study
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain and Central Nervous System Tumors, Unspecified Adult Solid Tumor, Protocol Specific
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may help solid tumor cells develop into normal cells.
- Trial name
- NCT00008086
- Testing
- calcitriol, carboplatin
- Where
- United States
- Sponsor
- University of Pittsburgh
Uveal Melanoma
Vascular Response to Brachytherapy Using Functional OCT
The purpose of this study is to learn how blood flows to tumors in patients treated with I-125 plaque brachytherapy for uveal melanoma.
- Trial name
- NCT01955941
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- OHSU Knight Cancer Institute
Age-Related Macular Degeneration, Neovascularization, Choroidal
Impact of Non-Exudative Type 1 MNV on AMD Progression
The overall goal of the proposed research project is to provide evidence that a specific subtype of neovascularization that may develop in eyes with age-related macular degeneration (AMD) prevents vision loss.
- Trial name
- NCT06125977
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Utah
Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
Efficacy and Safety of RTH258 Versus Aflibercept - Study 2
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection (6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal…
- Trial name
- HARRIER (NCT02434328)
- Testing
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Volunteers
- 1,048 people
- Sponsor
- Alcon Research
Myopia
The Immediate Effect of Defocus Spectacles On the Choroid Thickness Using Optical Coherence Tomography on Children
The purpose is to examine temporary changes in the subfoveal choroid thickness after removal and after resumed use of Defocus Incorporated Multiple Segment Spectacle Lenses (DIMS).
- Trial name
- TIDOCT (NCT06234189)
- Testing
- Defocus Incorporated Multiple Segment Spectacle Lenses (DIMS)
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Vejle Hospital
Epinephrine Toxicity, Cataract
The Effect of Intracameral Carbachol and Epinephrine on Choroidal Thickness
81 eyes of 81 patients undergoing cataract surgery were included in this prospective interventional study. During cataract surgery, intracameral carbachol was applied to 27 eyes, intracameral epinephrine was administered to 20…
- Conditions
- Epinephrine Toxicity, Cataract, Carbachol Adverse Reaction, Choroid Disease
- Trial name
- NCT05225597
- Testing
- Intracameral administration of epinephrine and carbachol during cataract surgery
- Where
- Turkey (Türkiye)
- Volunteers
- 81 people
- Sponsor
- Ordu University
Medulloblastoma, Ependymoma
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
Background: More than 130 primary tumors of the central nervous system (CNS) have been identified. Most affect less than 1,000 people in the United States each year.
- Conditions
- Medulloblastoma, Ependymoma, Pineal Region Tumors, Choroid Plexus Tumors
- Trial name
- NCT03173950
- Testing
- Nivolumab, EKG, MRI Brain and/or spine
- Where
- 3 sites in United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
Choroidal Neovascularization
Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study
Efficacy of monthly intravitreal anti-vascular endothelial growth factor (VEGF) associated to systemic immunosuppression in patients with Vogt-Koyanagi-Harada Disease and choroidal neovascularization. Minimum follow-up 12 months.
- Trial name
- NCT02015351
- Testing
- bevacizumab
- Where
- Brazil
- Volunteers
- 9 people
- Sponsor
- University of Sao Paulo
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
AMD, nAMD
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ASCENT (NCT05407636)
- Testing
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
- Where
- 181 sites in United States, Canada and 8 more
- Volunteers
- 735 people
- Sponsor
- AbbVie
Choroidal Neovascularization
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
The primary objective: *To measure the difference in the number of Ranibizumab therapies needed in 12 months in the Posterior Vitreous Detachment (PVD) positive and Posterior Vitreous Detachment (PVD) negative group.
- Trial name
- PVD (NCT01256632)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vision Research Foundation
Vein Occlusion, Macular Degeneration Choroidal Neovascularization
Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period
The goal of this clinical trial is to learn how various topical drops (bromfenac, loteprednol, and artificial tears) fare in alleviating post-intravitreal injection pain.
- Conditions
- Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
- Trial name
- NCT07090044
- Testing
- Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Retina Research Institute, LLC
Brain and Central Nervous System Tumors
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give…
- Trial name
- NCT00014573
- Testing
- aldesleukin, autologous tumor cell vaccine, filgrastim
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Maculopathy
AVIGA3 (Cohort 2.0)
Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central…
- Trial name
- AVIGA3 (NCT07255859)
- Testing
- Amsler Grid, AVIGA
- Where
- Singapore
- Volunteers
- 60 people
- Sponsor
- Tan Tock Seng Hospital
Choroidal Neovascularization, Age-Related Macular Degeneration
EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
This study will evaluate efficacy and safety for monthly ranibizumab 0.5 mg intravitreal injections in Asian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
- Trial name
- NCT00470678
- Testing
- ranibizumab
- Where
- 6 sites in South Korea, Taiwan
- Volunteers
- 95 people
- Sponsor
- Novartis
Neoplasms, Brain, Glioblastoma Multiforme
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor.
- Conditions
- Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms
- Trial name
- NCT03911388
- Testing
- G207
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00098761
- Testing
- laromustine
- Where
- 10 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pediatric Brain Tumor Consortium
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals